Health Condition 1: null- Schizophrenia
Conditions
Interventions
Intervention1: Asenapine: sublingual tablet 5 or 10 mg once, twice or thrice daily for 1 year
Intervention2: Iloperidone: 2 or 4 mg tablets, orally, once or twice daily for 1 year
Control Intervention
Sponsors
Pramukh Swami Medical College
Eligibility
Inclusion criteria
Inclusion criteria: 2) Prescribed any one of the following atypical antipsychotic drugs (study drugs) for the treatment of schizophrenia. • newer i.e. asenapine sublingual tablets or iloperidone oral tablets • older i.e. olanzapine oral tablets or risperidone oral tablets 3) Willing to comply with study related requirements as indicated by written informed consent from patient and his/ her legally acceptable representative (considering possible loss of insight in these patients, consent will also be taken from their legally acceptable representatives).
Exclusion criteria
Exclusion criteria: 1)History/ sign-symptom suggestive of pregnancy 2)Present history of known adverse effects associated with the study drugs to be studied (as mentioned in section 1 background).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events commonly associated with atypical antipsychotics between newer and corresponding older drugTimepoint: over 12 months period | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events reported in published literature that with reported in the studyTimepoint: over 12 months period | — |
Countries
India
Contacts
Public ContactDhruvika Kharadi
Department of Pharmacology, Pramukh Swami Medical College, Karamsad
Outcome results
None listed